louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02406703: The Impact of Chloroprocaine 3% for Ambulatory Foot Surgery on Perioperative Process Costs
Official title: Can the Choice of the Local Anesthetic Have an Impact on Ambulatory Surgery Perioperative Costs? Chloroprocaine for Popliteal Block in Outpatient Foot Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Impact of Anesthetic Choice on Costs
Keywords: local anesthesia
regional anesthetic
Lead sponsor: Ospedale Regionale Bellinzona e Valli
Sponsor class: OTHER
First posted: 2015-04-02
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: ASA I-III scheduled for elective, unilateral, ambulant minor foot surgery (percutaneous hallux valgus correction, osteotomies, tenotomies, mallet and hammer toes correction, screws and/or plaques removal)

Brief summary: Background and Objectives Short acting regional anesthetics have already been successfully employed for peripheral nerve blocks in an ambulatory surgery setting. However, the impact on direct and indirect perioperative costs comparing two different short-acting local anesthetics has not been performed, yet.

Methods In an observational study including 50 patients per group, patient undergoing popliteal block with chloroprocaine 3% or mepivacaine 1.5% for ambulatory minor foot surgery were compared. The primary outcome was the saving of both direct and indirect perioperative costs. Secondary outcomes were block success, onset time and block duration, patient satisfaction and unplanned outpatient visits or readmissions after discharge.


Eligibility criteria: Inclusion Criteria:

* ASA I-III scheduled for elective, unilateral, ambulant minor foot surgery (percutaneous hallux valgus correction, osteotomies, tenotomies, mallet and hammer toes correction, screws and/or plaques removal)

Exclusion Criteria:

* known allergy to drugs used in the study;
* coagulopathies, known neuropathy;
* pregnancy;
* chronic pain;
* drug or alcohol abuse;
* psychiatric disease or lack of competence affecting compliance and evidence of ongoing sepsis or local skin / subcutaneous tissues infections in the popliteal fossa.

Primary outcomes:
measure: Cost minimization analysis
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05715203: Aortic Stiffness in Patients with Genetic Aortopathies
Official title: Aortic Stiffness in Patients with Genetic Aortopathies: Intervention Analysis
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Rare Diseases
Aortic Stiffness
Connective Tissue Defect
Keywords: arterial stiffness
Ascending aortic aneurysm
pulse wave velocity
Lead sponsor: IRCCS Policlinico S. Donato
Sponsor class: OTHER
Collaborators: name: Istituto Auxologico Italiano
First posted: 2023-02-06
Enrollment: 250
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with ascending aortic aneurysms currently in follow.up at Cardiovascular Gentic Centre, IRCCS Policlinico San Donato.

Brief summary: The goal of this observational study is to study arterial stiffness in patients with thoracic ascending aortic aneurysms (TAA), either syndromic or non-syndromic. The main questions it aims to answer are:

* Stratification of aortic risk based on arterial stiffness; Compare measurements with morphological and haemodynamic features of the ascending thoracic aorta.

Participants will be asked to undergo non-invasive evaluation of blood pressure and arterial stiffness.

Detailed description: Recent studies have highlighted the role played by the aorta and the great arteries in the regulation of the blood pressure (BP) and peripheral blood flow. Similarly, the structural and functional alteration of the aortic wall having a genetic cause is highly associated with the onset of aneurysms, especially of the ascending aorta, for which it is essential to monitor the aortic stiffness, which is detectable through a non-invasive and non-radioactive method such as Pulse Wave Velocity (PWV). Despite literature studies correlating PWV in MFS, few evaluations of aortic stiffness in patients with syndromic TAA have been done and its potential correlations with other aneurysm markers.

Eligibility criteria: Inclusion Criteria:

* Subjects with AAT, either syndromic or non syndromic;
* Signed informed consent

Exclusion Criteria:

* Patients with early menopause and/or osteoporosis, rheumatic heart disease and active malignant tumours;
* Patients with acute and chronic inflammatory conditions such as: chronic liver disease, chronic renal insufficiency and diseases affecting the thyroid system;
* Seropositivity to HIV, HCV, HBsAg and SARS-CoV-2;
* Pregnancy

Primary outcomes:
measure: Pulse Wave Velocity
timeFrame: 18 months
Secondary outcomes:
Other outcomes:
Locations:
city: San Donato Milanese
country: Italy
facility: IRCCS Policlinico San Donato
state: Lombardia
Study officials:
affiliation: Cardiovascular-Gentic Centre, IRCCS Policlinico San Donato
name: Alessandro Pini
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06201403: Mechanical Properties of Peripheral and Accessory Respiratory Muscles in Chronic Obstructive Pulmonary Disease Patients
Official title: Mechanical Properties of Peripheral and Accessory Respiratory Muscles in Chronic Obstructive Pulmonary Disease Patients
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: COPD
Lead sponsor: Istanbul Medipol University Hospital
Sponsor class: OTHER
First posted: 2024-01-11
Enrollment: 66
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: COPD and healthy adults

Brief summary: The biomechanical properties of accessory respiratory muscles and peripheral muscles of COPD and healthy subjects will be measured and compared with the MyotonPro device.


Eligibility criteria: Inclusion Criteria:

* Being diagnosed with group C and D COPD according to GOLD staging
* Having been using the same medications for the last 4 weeks
* No additional comorbid diseases of the orthopedic, neurological or cardiac system

Exclusion Criteria:

* Presence of another respiratory system disease other than COPD
* Patients who have had an acute COPD exacerbation in the last 4 weeks
* Patients experiencing COPD exacerbations during the study protocol
* Presence of fatty tissue at the measurement points, which may impair the measurement quality.
* Have already participated in another clinical trial within the last 30 days that may affect the results of the study.

Inclusion Criteria for Healthy Cases

* Being over 18 years of age
* Not having any diagnosed chronic disease
* Not being a smoker

Primary outcomes:
measure: M.Sternocleidomastoideus (SCM) myotonometric measurement
timeFrame: 107 millisecond
measure: M. Trapezius myotonometric measurement
timeFrame: 107 millisecond
measure: M. Biceps brachii myotonometric measurement
timeFrame: 107 millisecond
measure: M. Pectoralis Major (PM) myotonometric measurement
timeFrame: 107 millisecond
measure: M. Rectus abdominis (RA) myotonometric measurement
timeFrame: 107 millisecond
measure: M.Rectus femoris myotonometric measurement
timeFrame: 107 millisecond
measure: M.Vastus lateralis myotonometric measurement
timeFrame: 107 millisecond
measure: M. Tibialis anterior myotonometric measurement
timeFrame: 107 millisecond
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Yedikule Chest Disease Hospital
state: Zeytinburnu
Study officials:
References:
Clinical trial NCT02138903: A Cardiac Ultrasound Evaluation of Two Types of Weaning Trials of Mechanical Ventilation for a First Weaning Trial
Official title: A Cardiac Ultrasound Evaluation of Two Types of Weaning Trials of Mechanical Ventilation for a First Weaning Trial
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Critical Care
Weaning of Mechanical Ventilation
Trans-thoracic Echocardiography
Mitral Doppler
Diastolic Function
Keywords: weaning
Cardiac
Echocardiography
Mechanical Ventilation
Lead sponsor: University Hospital, Clermont-Ferrand
Sponsor class: OTHER
First posted: 2014-05-15
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: ICU patients

Brief summary: Comparing the hemodynamic and cardiac effects of two types of weaning trials of mechanical ventilation in ICU patients of two French ICU.

Detailed description: Prospective clinical study in ICU with ventilated patients eligible to weaning trials of mechanical ventilation (ZEEP and tubing-spontaneous ventilation) comparing hemodynamic and cardiac effects evaluated by trans-thoracic echocardiography.

Eligibility criteria: Inclusion Criteria:

* Adult patients ventilated requiring first weaning trial of mechanical ventilation

  * Stable respiratory and hemodynamic conditions
  * Consent of patients or family
  * Arterial line
  * Ventilated patients

Exclusion Criteria:

-

Primary outcomes:
measure: left ventricular filling pressure
timeFrame: after 1 hour
Secondary outcomes:
measure: Comparison of other echocardiographic parameters of left ventricular filling pressures
timeFrame: after 1 hour
Other outcomes:
Locations:
city: Clermont-Ferrand
country: France
facility: CHU de Clermont-Ferrand
Study officials:
affiliation: University Hospital, Clermont-Ferrand
name: Sébastien PERBET
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01906203: Evaluation of Indices of Body Composition During Ultramarathon : Measure by Body Bioelectrical Impedance
Official title: Evaluation of Indices of Body Composition During Ultramarathon : Measure by Body Bioelectrical Impedance
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy Volunteers
Keywords: Ultramarathon
bioelectrical impedance
Phase-Angle
Lead sponsor: University Hospital, Clermont-Ferrand
Sponsor class: OTHER
Collaborators: name: University Hospital, Estaing
First posted: 2013-07-24
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Prospective cohort, monocentric non-randomized and interventional clinical study in ICU assessing the evolution of body composition using bioelectrical impedance analysis.

Detailed description: Prospective, monocentric non-randomized and interventional clinical study in ICU assessing the evolution of body composition using bioelectrical impedance analysis (phase angle, fat mass, muscle mass, fat-free mass, body water) before and after ultramarathon.

Eligibility criteria: Inclusion Criteria:

* Participation to ultramarathon

Exclusion Criteria:

* pregnancy women

Primary outcomes:
measure: Difference of fat-free mass, using bioelectrical impedance analysis
timeFrame: before and after ultramarathon of 105 km (at day 1)
Secondary outcomes:
measure: Difference of phase angle, using bioelectrical impedance analysis
timeFrame: at day 1(before and after ultramarathon)
measure: Correlation between order in the course,duration of course and indices of body composition
timeFrame: at day 1 (during ultramarathon of 105 km)
Other outcomes:
Locations:
city: Clermont-Ferrand
country: France
facility: CHU Clermont-Ferrand
Study officials:
affiliation: University Hospital, Clermont-Ferrand
name: Sébastien PERBET
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05821803: The Effect of Exercise Training and Arch Supported Insoles on Balance and Vertical Jump Performance in Football Players With Foot Pronation Deformity
Official title: The Effect of Exercise Training and Arch Supported Insoles on Balance and Vertical Jump Performance in Football Players With Foot Pronation Deformity: Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Foot; Pronation, Congenital
Keywords: Foot pronation
Insoles
Footcore exercises
Lead sponsor: Yeditepe University
Sponsor class: OTHER
Collaborators: name: FootBalance
First posted: 2023-04-20
Enrollment: 30
Sex: MALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to investigate the effects of foot pronation exercises and arch support insoles on balance and vertical jump test in football players.

Detailed description: The study took place in FootBalance Turkey, which works on foot analysis and insoles.

30 professional football players with pronation who divided into two groups. The football players in the Experimental Group used insoles and also participated the foot core exercise program twice a week for 4 weeks duration. The football players in the Control Group just used the insoles.We used the FootBalance assessmnet system for insoles. Navicular Drop Test, Y Balance Test, Flamingo Testand Vertical Jump Test applied to evalute foot pronation, dynamic balance, static balance and jump performace respectively.

Eligibility criteria: Inclusion Criteria:

1. Voluntary participation in research
2. To be between the ages of 18-45
3. Overpronation foot ( navicular drop test over 10 mm and FootBalance device with visual display)
4. Professional football players at least 5 years

Exclusion Criteria:

1. History of surgery for musculoskeletal structures in both lower extremities
2. History of fracture in both lower extremities
3. Acute injury of the musculoskeletal structures of other joints of the lower extremity affecting joint function and integrity in the last 3 months
4. Have any other knee pathology
5. Balance or vestibular disorder

Primary outcomes:
measure: Navicular Drop Test
timeFrame: 4 weeks
measure: Y Balance Test/ Dynamic Balance Evaluation
timeFrame: 4 weeks
measure: Flamingo Balance Test/ Static Balance Evalutaion
timeFrame: 4 weeks
measure: Vertical Jump Test
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: FootBalance Merkez
state: Şişli
Study officials:
References:
Clinical trial NCT06778603: B7-H3 NIR Imaging for Osteosarcoma Surgery
Official title: Resection of Osteosarcoma in Limbs Navigated by B7H3-based NIR Lmaging: a Prospective, Single-center,Single-arm, Exploratory Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Osteosarcoma
Resection Margins
B7-H3 Probe
Local Recurrence
Keywords: osteosarcoma
resection margins
B7-H3 Targeted Probe
local recurrence rate
Lead sponsor: Peking University People's Hospital
Sponsor class: OTHER
Collaborators: name: Simcere Pharmaceutical Group Limited
First posted: 2025-01-16
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Complete removal of all tumor tissue with a wide surgical margin is essential for the treatment of osteosarcoma (OS). However, it's difficult, sometimes impossible, to achieve due to the invisible small satellite lesions and blurry tumor boundaries. Besides, intraoperative frozen-section analysis of resection margins of OS is often restricted by the hard tissues around OS, which makes it impossible to know whether a negative margin is achieved. Herein, based on the high expression of B7-H3 in OS, a targeted probe B7H3-IRDye800CW is synthesized by conjugating anti-B7H3 antibody and IRDye800CW. This trial is aimed to investigate R0-resection rate and 2-y local recurrence rate after using this probe in Musculoskeletal tumor surgery for osteosarcoma as well as the safety parameters of this probe in human.


Eligibility criteria: Inclusion Criteria:

* 1. Patients with histologically confirmed osteosarcoma of the limbs.
* 2. the patients has not undergone tumor resection.
* 3. Age between 18 and 60 years old.
* 4. No prior systemic treatment for osteosarcoma.
* 5. Measurable disease as assessed by imaging studies (e.g., MRI, CT).
* 6. Adequate bone marrow, liver, and renal function.
* 7. Written informed consent obtained from the patient.

Exclusion Criteria:

* 1. History of other malignancies within the past 5 years.
* 2. Pregnancy or lactation.
* 3. Known hypersensitivity to any component of the B7H3-based NIR imaging agent.
* 4. Uncontrolled intercurrent illness that would preclude safe study participation.
* 5. Prior radiation therapy to the target lesion.
* 6. Any medical condition that would compromise the patient's ability to undergo surgery or comply with study procedures.
* 7.Patients not able to sign the Informed Consent.

Primary outcomes:
measure: Safety
timeFrame: 21 days
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Musculoskeletal Tumor Center
state: Beijing
Study officials:
References:
citation: Zeng F, Li C, Wang H, Wang Y, Ren T, He F, Jiang J, Xu J, Wang B, Wu Y, Yu Y, Hu Z, Tian J, Wang S, Tang X. Intraoperative Resection Guidance and Rapid Pathological Diagnosis of Osteosarcoma using B7H3 Targeted Probe under NIR-II Fluorescence Imaging. Adv Sci (Weinh). 2024 Sep;11(33):e2310167. doi: 10.1002/advs.202310167. Epub 2024 Mar 19.
Clinical trial NCT00348803: Gene Mutations in Secondary Pulmonary Hypertension
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Chronic Thromboembolic Pulmonary Hypertension
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2006-07-06
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: DEFINED_POPULATION
Time perspective: PROSPECTIVE

Brief summary: As a pulmonary hypertension center, we have created a database that prospectively tracks patients with different forms of secondary pulmonary hypertension. Records include genetic analysis, and clinical and hemodynamic profiles.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of CTEPH and patient consent

Exclusion Criteria:

* No patient consent

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Medical University of Vienna
Study officials:
affiliation: Medical University of Vienna
name: Irene Lang, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06384703: The Relationship Between Microbiota and Coronary Ectasia
Official title: The Evaluation of the Relationship Between Coronary Ectasia And Trimethylamine N Oxide
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Ectasia
Microbial Disease
Keywords: microbiota
endothelium
Lead sponsor: Konya Beyhekim Training and Research Hospital
Sponsor class: OTHER_GOV
Collaborators: name: Necmettin Erbakan University
First posted: 2024-04-25
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: In this study, patients with chronic stable angina who underwent coronary angiography were included after exclusion criteria.

Brief summary: Introduction: It is now known that the microbiota is far beyond the microbial communities living in certain parts of our body and functions like a metabolic organ. In addition, the microbiota, through its metabolites, is involved in the pathophysiology or progression of a wide range of diseases, from atherosclerotic diseases to metabolic diseases and even neurological diseases. Among these metabolites, trimethylamine n-oxide metabolite has been shown to be particularly effective on atherosclerotic heart diseases.


Eligibility criteria: Inclusion Criteria:

* over 18 years old
* not having occlusive coronary artery disease
* having coronary ectasia

Exclusion Criteria:

* patients with chronic kidney disease,
* revascularized coronary artery disease,
* previously documented critical coronary stenosis,
* acute or chronic inflammatory disease,
* rheumatologic disease,
* known active malignant disease,
* heart failure,
* moderate-to-severe valvular pathology
* patients who were on any steroid or immunosuppressive therapy

Primary outcomes:
measure: death
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Konya
country: Turkey
facility: Necmettin Erbakan University
Study officials:
affiliation: Necmettin Erbakan University
name: Yakup Alsancak
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06350903: Suppression With Empagliflozin as an Alternative To High-Fat Low-Carbohydrate Diet for Myocardial F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Imaging
Official title: Suppression With Empagliflozin as an Alternative To High-Fat Low-Carbohydrate Diet for Myocardial FDG-PET Imaging
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Myocardial Suppression
Lead sponsor: Montreal Heart Institute
Sponsor class: OTHER
First posted: 2024-04-08
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: The overall objective of this study is to assess if the empagliflozin has the potential to substitute the high fat low carb (HFLC) diet for the preparation of cardiovascular FDG-PET studies.

Detailed description: The overall objective of this study is to assess if the SGLT2 inhibitor empagliflozin has the potential to substitute the high fat low carb (HFLC) diet for the preparation of cardiovascular FDG-PET studies. This study will evaluate if an acute administration of empagliflozin (tablets of 10 and/or 25 mg) combined with fasting can sufficiently increase the BHB levels, a proxy of myocardial FDG uptake.

Eligibility criteria: Inclusion Criteria:

1. Aged 18 to 70 years
2. Ability to follow the HFLC diet
3. Ability to provide informed consent

Exclusion Criteria:

1. Treated with SGLT2 inhibitors
2. History of hypersensitivity or allergy to empagliflozin
3. Hypotension with blood pressure \<100/65 mmHg
4. Strict vegan
5. Pregnancy
6. Breastfeeding
7. Type I or type II diabetes
8. Renal failure with Estimated Glomerular Filtration Rate (eGFR) \<60 mL/min/1.72m2
9. Receiving steroids
10. History of diabetic ketoacidosis (DKA)
11. History of hypoglycemia
12. Any condition that, in the opinion of the investigator, could compromise the participation in the study

Primary outcomes:
measure: Levels of serum Beta-hydroxybutyrate (BHB) mmol/L
timeFrame: 1 day
Secondary outcomes:
measure: Proportions of serum Beta-hydroxybutyrate (BHB) >0.5 mmol/L
timeFrame: 1 day
measure: Proportions of glycemia levels (mmol/L) <3.5 mmol/L
timeFrame: 1 day
measure: Acceptability and tolerance of each protocol, as reported by patients by a dedicated survey.
timeFrame: Through study completion, up to 3 months.
Other outcomes:
Locations:
Study officials:
References: